Group A-beta Hemolytic Streptococci에 의한 소아 인두편도염에 있어서 Cefdinir의 항균력과 임상적 및 세균학적 효과에 관한 연구

최근 국내 erythromycin 내성률이 증가하는 추세임을 보고하였고 erythromycin의 경우 내성의 증가는 항생제 사용량의 증가와 일치하고 있음을 보고하였다. 그래서 macrolide에 의한 내성균주의 확산을 막고 임상에서 보고되는 penicillin에 의한 치료 실패를 줄이기 위해 A군 연쇄구균 치료에 제일차 약물로 cephalosporin을 고려할 수 있다. Cefdinir의 A군 연쇄구균에 대한 항균력과 인두 편도염에 대한 우수한 임상효과 및 높은 안전성을 미루어 볼 때, Cefdinir는 A군 연쇄구균에 의한 소아 인두 편도염에 유효한 항생제로 사용될 수 있다. Objective : To determine the clinical and bacteriologic efficacy and safety of Cefdinir in acute pharyngitis and pharyngotonsillitis caused by group A beta hemolytic streptococci in pediatric patients. Methods : Children aged 3 through 12 years who visited the hospitals enrolled in this study with signs and symptoms of pharyngitis or pharyngotonsillitis since May to December 2002, were taken throat culture and given Cefdinir(12 mg/kg/day, in three divided doses) for 7 days. Two hundred thirty five patients were enrolled and 90 patients who showed positive culture results were followed up for the signs and symptoms during the treatment to determine clinical efficacy. Follow-up culture were done at the end of the study and bacteriologic efficacy was determined Results : Ninety out of 235 patients who visited the hospitals with the signs and symptoms of pharyngitis showed positive growth on throat culture. Seventy nine patients were clinically and microbiologically assessable. The bacteriologic eradication rates of S. pyogenes were 100% in all the children treated with Cefdinir. Clinical cure rates were not different between less than 7 days-treated group(75%) and just 7 days-treated group(98.6%)(P=0.077). Two patients reported adverse reaction during Cefdinir treatment. Antimicrobial sensitivity of Cefdinir against S. pyogenes was 100% with range of MIC being less than 0.5 ㎍/mL. Conclusion : It seems that Cefdinir is one of reliable and well-tolerated drugs for the treatment of group A beta hemolytic streptococcal pharyngotonsillitis in children. It needs to be investigated short term efficacy in terms of improving drug compliance and impact of economic point of view. We can recognized that still high rate of the erythromycin resistant group A streptococci in our community should be monitored every year.